Personalised Cancer Care

not specified
+ show speakers and program


Friday, September 7th
08:00-08:15 Opening and Welcome: Enrico Mihich, Hans-P Huber, A.-L. Børresen-Dale
08:15-09:00 Opening keynote: Leroy Hood, Institute for Systems Biology, Seattle, WA, USA
Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine


Session I: Genetic Profiling of Patients, Prediction of Risk and Late Side Effects
09:00-09:35
Bruce Ponder, Cancer Research UK, Cambridge Research Institute, UK.
"Common Genetic Variants and Clinical Applications: Lessons from Breast and Prostate Cancer"
09:35-09:50
Discussion
09:50-10:25
Vessela N. Kristensen, Akershus University Hospital, Norway.
"Allele Specific Expression - Can it lead us to the risk allele?"
10:25-10:40
Discussion
10:40-11:10
Coffee
11:10-11:45
Eiliv Lund, The University of Tromsø, Norway.
"Searching for the Last Stage of Breast Cancer Carcinogenesis - the Norwegian Women and Cancer Postgenome Study"
11:45-12:00
Discussion
12:00-13:00
Lunch and posters
13:00-13:35
Patricia Ganz, UCLA School of Public Health, USA.
"Understanding the Late Effects of Cancer Treatment: Host Factors and Personal Vulnerability"
13:35-13:50
Discussion


Session II: Molecular Profiling of Tumors and Metastases
13:50-14:25 Mike Stratton, Wellcome Trust Sanger Institute, UK.
"Evolution of the Cancer Genome"
14:25-14:40 Discussion
14:40-15:10 Coffee
15:10-15:45 Jun Wang, BGI, China.
"Genetic Analysis of Cancers and Cancer Progression Using Single-Cell Sequencing"
15:45-16:00
Discussion
16:00-16:35 Lao Saal, Lund University, Sweden.
"Deep Sequencing Approaches for Personalizing Breast Cancer Biomarkers in South Sweden"
16:35-16:50
Discussion


Saturday, September 8th


Session II continued
08:30-09:05
Zoltan Szallasi, Technical University of Denmark, Denmark.
"Genome Scale Molecular Profiling provides a Robust Way to Identify and Quantify Key Biological Processes Driving Cancer with the Potential to personalize Cancer Treatment"
09:05-09:20
Discussion
9:20-10:55
Carlos Caldas, Cancer Research UK, Cambridge Research Institute, UK.
"A New Molecular Taxonomy of Breast Cancer"
10:55-11:10
Discussion
11:10-11:40
Coffee


Session III: Tumor-host Microenvironment Interaction and Metabolism
11:40-12:15
Mina Bissell, Lawrence Berkeley National Laboratory, USA.
"Thinking in 3-dimension to discover New Targets for Therapy"
12:15-12:30
Discussion
12.30-13:05
Larry Norton, Memorial Sloan-Kettering Cancer Center, USA.
"Unraveling Clinical Enigmas: Implications of Cancer Cell Mortality and Tissue Geometry"
13:05-13:20
Discussion
13:20-14:20
Lunch and posters
14.20-14:55
Celeste Simon, University of Pennsylvania School of Medicine, USA.
"HIFs,Myc, and Tumor Metabolism"
14:55-15:10
Discussion
15:10-15:45
Arnold Levine, Princeton University, USA.
"P53 Allele Specific Synthetic Lethal Drugs"
15:45-16:00
Discussion
16:00-16:30
Coffee


Session IV: Targeted Therapy
16:30-17:05
Gordon Mills, MD Anderson Cancer Center, USA.
"Overcoming Challenges to the Delivery of Personalized Medicine"
17:05-17:20
Discussion
17:20-18:55
Rene Bernards, The Netherlands Cancer Institute, Netherlands.
"Using Functional Genetics to Optimize the Treatment of Cancer"
18:55-19:05
Discussion
19:05-19:40
Joe Gray, Lawrence Berkley National Laboratory, USA.
"Systems Approaches to Targeted Therapy - Genomics and Beyond"
19:40-19:55
Discussion


Sunday, September 9th


Session V: Translation
08:30-09:05
Olli Kallioniemi, FIMM, Finland.
"Translational Cancer Genomics and Personalized Medicine"
09:05-09:20
Discussion
09:20-09:55
Anne-Lise Børresen-Dale, Oslo University Hospital, Norway.
"Breast Tumor Heterogeneity; A Challenge for Translation"
09:55-10:10
Discussion
10:10-10:40
Coffee
10:40-11:15
Laura van`t Veer, University of California, San Francisco, USA.
"Biomarker Indication for Increased Likelihood of Therapeutic Response"
11:15-11:30
Discussion
11:30-12:05
Desmond Powe, Nottingham University Hospitals, UK.
"Accumulating and Confirmatory Evidence for Beta-blockers offering Protection Against Metastasis"
12:05:12:20
Discussion
12:20-13:20
Lunch


Session VI: Informed Consent Ethical Challenges, and Communication
13:20-13:50
Stephen H. Friend, Sage Bionetworks, USA
13:50-14:20
Nance Guilmartin, Center for Leadership, Florida International University, USA
14:20-15:50
Sissel Rogne, The Norwegian Biotechnology Advisory Board, Norway
15:50-16:10
Discussion
16:10-16:30
Summing up, by Kurt S. Zänker, Fritz-Bender-Foundation, Munich, and University Witten/Herdecke, Germany

7 Sep - 9 Sep 2012
Oslo
Norway
meeting website